OH2
AXP000089.1 · Oncolytic virus
- Platform
- HSV-2 (strain HG52, ICP34.5- ICP47-)
- Originator
- Binhui Biopharmaceutical
- Sponsor
- Binhui Biopharmaceutical
Names
| Name | Type | Source |
|---|---|---|
| OH2 ambiguous | preferred name, code | curator, ncit |
| OH2 injection | synonym | ctgov |
| oHSV2hGM-CSF | synonym | curator |
Virus
- Role
- Oncolytic
- Family
- Orthoherpesviridae
- Virus
- herpes simplex virus 2 (NCBI Taxonomy 10310)
- Strain
- HG52
- Replication
- conditionally replicating
- Modifications
- ICP34.5 and ICP47 deleted; ICP6 mutated
- Transgenes
- CSF2
- Route
- intratumoral, intravesical
- Source
- evidence
Cross-references
- NCI Thesaurus
- C172106
Approvals
No regulatory approval recorded.
Clinical trials (14)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07854522 | A Study of QL1706 Combined With OH2 Injection in Perioperative Treatment of Stage III Resectable Acral Melanoma | Not yet recruiting | Phase 4 | 2026-10 | 2029-09 | 76 | Acral Melanoma; Melanoma |
| NCT05954091 | OH2 Administered by Intratumoral Injection | Not yet recruiting | Phase 1 | 2025-09-01 | 2027-07-01 | 29 | Solid Tumor |
| NCT05648006 | First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer | Terminated | Phase 2 | 2023-10-17 | 2024-04-15 | 7 | Advanced Colorectal Carcinoma |
| NCT05698459 | OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer | Recruiting | Phase 1 | 2023-05-05 | 2025-08 | 12 | Advanced Liver Cancer |
| NCT05868707 | OH2 Injection in Melanoma | Recruiting | Phase 3 | 2023-03-08 | 2026-03 | 340 | Melanoma |
| NCT05232136 | OH2 Oncolytic Viral Therapy in Non-Muscle-Invasive Bladder Cancer | Unknown | Phase 1/2 | 2022-07-11 | 2025-06 | 30 | Non-muscle-invasive Bladder Cancer |
| NCT05248789 | OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer | Terminated | Phase 2 | 2022-05-25 | 2024-10-28 | 4 | Advanced Bladder Carcinoma |
| NCT05235074 | OH2 Oncolytic Viral Therapy in Central Nervous System Tumors | Completed | Phase 1/2 | 2021-11-16 | 2026-07-23 | 40 | Central Nervous System Tumors |
| NCT05070221 | Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis | Unknown | Phase 1 | 2021-10-01 | 2023-10-31 | 30 | Melanoma Stage IV |
| NCT05068453 | Study of Oncolytic Virus in Combination With HX-008 and Radiotherapy in Melanoma Patients With Liver Metastasis | Unknown | Phase 1 | 2021-10-01 | 2023-10-31 | 15 | Melanoma Stage IV |
| NCT04637698 | OH2 Oncolytic Viral Therapy in Pancreatic Cancer | Terminated | Phase 1/2 | 2021-02-02 | 2023-05-04 | 5 | Pancreatic Cancer |
| NCT04616443 | OH2 Injection in Combination With HX008 for Melanoma. | Recruiting | Phase 1/2 | 2020-12-01 | 2025-11-30 | 60 | Melanoma |
| NCT03866525 | OH2 Oncolytic Viral Therapy in Solid Tumors | Recruiting | Phase 1/2 | 2019-04-02 | 2025-08-30 | 300 | Gastrointestinal Cancer; Solid Tumor |
| NCT04386967 | OH2 Injection in Solid Tumors | Completed | Phase 1/2 | 2018-11-22 | 2026-06-02 | 44 | Melanoma; Solid Tumor |
Unconfirmed matches (1)
Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions | Matched by |
|---|---|---|---|---|---|---|---|---|
| NCT07382531 | OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors | Recruiting | Phase 1/2 | 2023-09-07 | 2027-12-31 | 30 | Solid Tumor | name in title: OH2 injection |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 39915002 | Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights. | Journal for immunotherapy of cancer | 2025 | cited by trial NCT04386967 |
| PMID 38537773 | OH2 oncolytic virus: A novel approach to glioblastoma intervention through direct targeting of tumor cells and augmentation of anti-tumor immune responses. | Cancer letters | 2024 | cited by trial NCT05235074 |
| PMID 34757194 | cited by trial NCT03866525 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 22780924 | [Construction of a new oncolytic virus oHSV2hGM-CSF and its anti-tumor effects]. | Zhonghua zhong liu za zhi [Chinese journal of oncology] | 2012 | name in title: oHSV2hGM-CSF |
Notes
Oncolytic HSV-2 armed with GM-CSF, the most clinically advanced HSV-2-based oncolytic. Dosed intratumorally in solid tumours and melanoma and intravesically in bladder cancer.
How to cite
OH2 (AXP000089.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000089.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.